Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Receivables - Other (2016 - 2025)

Historic Receivables - Other for ImmunityBio (IBRX) over the last 11 years, with Q3 2025 value amounting to $1.7 million.

  • ImmunityBio's Receivables - Other rose 13086.42% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 13086.42%. This contributed to the annual value of $293000.0 for FY2024, which is 8548.79% down from last year.
  • ImmunityBio's Receivables - Other amounted to $1.7 million in Q3 2025, which was up 13086.42% from $204000.0 recorded in Q2 2025.
  • Over the past 5 years, ImmunityBio's Receivables - Other peaked at $5.0 million during Q2 2022, and registered a low of $204000.0 during Q2 2025.
  • For the 5-year period, ImmunityBio's Receivables - Other averaged around $1.9 million, with its median value being $1.8 million (2022).
  • Its Receivables - Other has fluctuated over the past 5 years, first soared by 171150.44% in 2021, then tumbled by 8015.91% in 2025.
  • Over the past 5 years, ImmunityBio's Receivables - Other (Quarter) stood at $1.3 million in 2021, then soared by 41.79% to $1.9 million in 2022, then increased by 6.83% to $2.0 million in 2023, then plummeted by 63.89% to $729000.0 in 2024, then soared by 130.86% to $1.7 million in 2025.
  • Its Receivables - Other was $1.7 million in Q3 2025, compared to $204000.0 in Q2 2025 and $424000.0 in Q1 2025.